Low-dose insulin therapy in patients with cystic fibrosis and early-stage insulinopenia prevents deterioration of lung function: a 3-year prospective study

被引:30
作者
Kolouskova, Stanislava
Zemkova, Daniela
Bartosova, Jana [1 ]
Skalicka, Veronika
机构
[1] Charles Univ Prague, Dept Pediat, Fac Med 2, CZ-15006 Prague 5, Czech Republic
关键词
cystic fibrosis; cystic fibrosis related diabetes; insulinopenia; insulin treatment; pulmonary function tests; DIABETES-MELLITUS; GLUCOSE-INTOLERANCE; SENSITIVITY; CHILDREN; ADOLESCENTS; MANAGEMENT; RESISTANCE; CLEARANCE; GLARGINE; TRENDS;
D O I
10.1515/JPEM.2011.050
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Cystic fibrosis related diabetes (CFRD) is an insulinopenic condition. We aimed to detect insulinopenia early and to evaluate the impact of low dose insulin on nutritional status and forced expiratory volume in first second (FEV1). Out of 142 cystic fibrosis patients (CFpts) older than 10 years, 28 with abnormal oral glucose tolerance test in spite of normal fasting glycemia were found to have decreased first phase insulin release and started low dose insulin therapy (median age 15.4 years). Sex and age matched CFpts with normal glucose tolerance (NGT) were observed for comparison. Whereas nutritional status improved following 3 years of insulin administration, FEV1 stabilized in insulin-treated insulinopenic subjects (73.8 +/- 4.3% vs. 73.5 +/- 4.4 %), but decreased in the parallel group with NGT who remained without insulin treatment (71.1 +/- 3.8 % vs. 61.0 +/- 4.0 %; p=0.001). We conclude that low dose insulin improves nutritional status and stabilizes pulmonary functions. Regular estimation of stimulated insulin secretion in CFpts may allow optimizing treatment.
引用
收藏
页码:449 / 454
页数:6
相关论文
共 36 条
[1]  
ABDULKARIM FW, 1986, ARCH PATHOL LAB MED, V110, P602
[2]   INSULIN SENSITIVITY AND METABOLIC-CLEARANCE RATE OF INSULIN IN CYSTIC-FIBROSIS [J].
AHMAD, T ;
NELSON, R ;
TAYLOR, R .
METABOLISM-CLINICAL AND EXPERIMENTAL, 1994, 43 (02) :163-167
[3]   STANDARDIZATION OF IVGTT TO PREDICT IDDM [J].
BINGLEY, PJ ;
COLMAN, P ;
EISENBARTH, GS ;
JACKSON, RA ;
MCCULLOCH, DK ;
RILEY, WJ ;
GALE, EAM .
DIABETES CARE, 1992, 15 (10) :1313-1316
[4]   Clinical effects of early treatment with insulin glargine in patients with cystic fibrosis and impaired glucose tolerance [J].
Bizzarri, C ;
Lucidi, V ;
Ciampalini, P ;
Bella, S ;
Russo, B ;
Cappa, M .
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 2006, 29 (03) :RC1-RC4
[5]  
Blaha P, 1993, Cesk Pediatr, V48, P621
[6]   Diabetes as a Determinant of Mortality in Cystic Fibrosis [J].
Chamnan, Parinya ;
Shine, Brian S. F. ;
Haworth, Charles S. ;
Bilton, Diana ;
Adler, Amanda I. .
DIABETES CARE, 2010, 33 (02) :311-316
[7]   BETA-CELL FUNCTION, PERIPHERAL SENSITIVITY TO INSULIN AND ISLET CELL AUTOIMMUNITY IN CYSTIC-FIBROSIS PATIENTS WITH NORMAL GLUCOSE-TOLERANCE [J].
CUCINOTTA, D ;
NIBALI, SC ;
ARRIGO, T ;
DIBENEDETTO, A ;
MAGAZZU, G ;
DICESARE, E ;
COSTANTINO, A ;
PEZZINO, V ;
DELUCA, F .
HORMONE RESEARCH, 1990, 34 (01) :33-38
[8]  
Cystic Fibrosis Foundation Patients Registry, 1997, CYST FIBR FDN ANN DA
[9]   The 1997 American Diabetes Association criteria versus the 1985 World Health Organization criteria for the diagnosis of abnormal glucose tolerance - Poor agreement in the Hoorn study [J].
De Vegt, F ;
Dekker, JM ;
Stehouwer, CDA ;
Nijpels, G ;
Bouter, LM ;
Heine, R .
DIABETES CARE, 1998, 21 (10) :1686-1690
[10]   Clinical improvement in cystic fibrosis with early insulin treatment [J].
Dobson, L ;
Hattersley, AT ;
Tiley, S ;
Elworthy, S ;
Oades, PJ ;
Sheldon, CD .
ARCHIVES OF DISEASE IN CHILDHOOD, 2002, 87 (05) :430-431